Downregulated miR‑130a enhances the sensitivity of acute myeloid leukemia cells to Adriamycin

Liu,Huimin; Liu,Min; Zhang,Jiangzhao; Liang,Yan

doi:10.3892/mmr.2020.11375

Downregulated miR‑130a enhances the sensitivity of acute myeloid leukemia cells to Adriamycin

Authors:
- Huimin Liu
- Min Liu
- Jiangzhao Zhang
- Yan Liang
View Affiliations

Affiliations: Department of Hematology, Jingzhou Central Hospital, Jingzhou, Hubei 434020, P.R. China
Published online on: July 28, 2020 https://doi.org/10.3892/mmr.2020.11375
Pages: 2810-2816
Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

MicroRNA (miR)‑130a has been reported to promote cancer growth; however, its role during acute myeloid leukemia (AML) is not completely understood. In the present study, the effects of miR‑130a on the sensitivity of AML cells to Adriamycin (Adr) were investigated. 5‑Aza‑2'‑deoxycytidine (5‑Aza‑dC) was used to stimulate Adr resistance in AML cells, and cell viability and miR‑130a expression were determined using the Cell Counting Kit‑8 (CCK‑8) assay and reverse transcription‑quantitative PCR, respectively. miR‑130a overexpression and knockdown in Adr‑resistant AML cells was performed to investigate the proliferative and invasive abilities of the cells using CCK‑8 and Transwell assays, respectively. Furthermore, the effects of miR‑130a on the expression of epithelial‑mesenchymal transition (EMT)‑related proteins in Adr‑resistant AML cells were detected using western blot analysis. Pre‑treatment with 5‑Aza‑dC enhanced the cell viability and miR‑130a expression of Adr‑treated AML cells. Adr and miR‑130a expression showed a dose‑dependent relationship, with miR‑130a expression decreasing with increasing Adr concentrations. Moreover, miR‑130a overexpression alleviated the inhibitory effects of Adr on cell viability and invasion, while miR‑130a knockdown enhanced the sensitivity of AML cells to Adr. Furthermore, Adr exerted an inhibitory effect on EMT in AML cells, which was rescued by miR‑130a overexpression and enhanced by miR‑130a knockdown. miR‑130a knockdown also increased the sensitivity of AML cells to Adr by decreasing cell viability, invasion and EMT. Therefore, miR‑130a knockdown is a potential therapeutic strategy for Adr‑resistant AML.

View Figures

View References

1	Li S, Mason CE and Melnick A: Genetic and epigenetic heterogeneity in acute myeloid leukemia. Curr Opin Genet Dev. 36:2810–106. 2016. View Article : Google Scholar
2	Juliusson G and Hough R: Leukemia. Prog Tumor Res. 43:87–100. 2016. View Article : Google Scholar : PubMed/NCBI
3	De Kouchkovsky I and Abdul-Hay M: Acute myeloid leukemia: A comprehensive review and 2016 update. Blood Cancer J. 6:e4412016. View Article : Google Scholar : PubMed/NCBI
4	Yamamoto JF and Goodman MT: Patterns of leukemia incidence in the United States by subtype and demographic characteristics, 1997–2002. Cancer Causes Control. 19:379–390. 2008. View Article : Google Scholar : PubMed/NCBI
5	Pulte D, Gondos A and Brenner H: Expected long-term survival of patients diagnosed with acute myeloblastic leukemia during 2006–2010. Ann Oncol. 21:335–341. 2010. View Article : Google Scholar : PubMed/NCBI
6	Meyers J, Yu Y, Kaye JA and Davis KL: Medicare fee-for-service enrollees with primary acute myeloid leukemia: An analysis of treatment patterns, survival, and healthcare resource utilization and costs. Appl Health Econ Health Policy. 11:275–286. 2013. View Article : Google Scholar : PubMed/NCBI
7	Bose P, Vachhani P and Cortes JE: Treatment of relapsed/refractory acute myeloid leukemia. Curr Treat Options Oncol. 18:172017. View Article : Google Scholar : PubMed/NCBI
8	McCall MN, Kim MS, Adil M, Patil AH, Lu Y, Mitchell CJ, Leal-Rojas P, Xu J, Kumar M, Dawson VL, et al: Toward the human cellular microRNAome. Genome Res. 27:1769–1781. 2017. View Article : Google Scholar : PubMed/NCBI
9	Mohr AM and Mott JL: Overview of microRNA biology. Semin Liver Dis. 35:3–11. 2015. View Article : Google Scholar : PubMed/NCBI
10	Rupaimoole R and Slack FJ: MicroRNA therapeutics: Towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 16:203–222. 2017. View Article : Google Scholar : PubMed/NCBI
11	Acunzo M, Romano G, Wernicke D and Croce CM: MicroRNA and cancer-a brief overview. Adv Biol Regul. 57:1–9. 2015. View Article : Google Scholar : PubMed/NCBI
12	Wang X, Chen H, Bai J and He A: MicroRNA: An important regulator in acute myeloid leukemia. Cell Biol Int. 41:936–945. 2017. View Article : Google Scholar : PubMed/NCBI
13	Li Q, Song W and Wang J: TUG1 confers Adriamycin resistance in acute myeloid leukemia by epigenetically suppressing miR-34a expression via EZH2. Biomed Pharmacother. 109:1793–1801. 2019. View Article : Google Scholar : PubMed/NCBI
14	Szymczyk A, Chocholska S, Macheta A, Szczepanek D, Hus M and Podhorecka M: Assessment of microRNA expression in leukemic cells as predictors of sensitivity to purine nucleoside analogs, fludarabine and cladribine, in chronic lymphocytic leukemia patients. Cancer Manag Res. 11:5021–5031. 2019. View Article : Google Scholar : PubMed/NCBI
15	Ding C, Chen SN, Macleod RAF, Drexler HG, Nagel S, Wu DP, Sun AN and Dai HP: miR-130a is aberrantly overexpressed in adult acute myeloid leukemia with t(8;21) and its suppression induces AML cell death. Ups J Med Sci. 123:19–27. 2018. View Article : Google Scholar : PubMed/NCBI
16	Wei H, Cui R, Bahr J, Zanesi N, Luo Z, Meng W, Liang G and Croce CM: miR-130a deregulates PTEN and stimulates tumor growth. Cancer Res. 77:6168–6178. 2017. View Article : Google Scholar : PubMed/NCBI
17	Yin S, Zhang Q, Wang Y, Li S and Hu R: MicroRNA-130a regulated by HPV18 E6 promotes proliferation and invasion of cervical cancer cells by targeting TIMP2. Exp Ther Med. 17:2837–2846. 2019.PubMed/NCBI
18	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
19	Lagunas-Rangel FA, Chavez-Valencia V, Gomez-Guijosa MA and Cortes-Penagos C: Acute myeloid leukemia-genetic alterations and their clinical prognosis. Int J Hematol Oncol Stem Cell Res. 11:328–339. 2017.PubMed/NCBI
20	Paschka P, Schlenk RF, Gaidzik VI, Habdank M, Krönke J, Bullinger L, Späth D, Kayser S, Zucknick M, Götze K, et al: IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol. 28:3636–3643. 2010. View Article : Google Scholar : PubMed/NCBI
21	Kater L, Claffey J, Hogan M, Jesse P, Kater B, Strauss S, Tacke M and Prokop A: The role of the intrinsic FAS pathway in Titanocene Y apoptosis: The mechanism of overcoming multiple drug resistance in malignant leukemia cells. Toxicol In Vitro. 26:119–124. 2012. View Article : Google Scholar : PubMed/NCBI
22	Madanat YF, Kalaycio ME and Nazha A: Advances in acute myeloid leukemia genomics, where do we stand in 2018? Acta Med Acad. 48:35–44. 2019.PubMed/NCBI
23	Rivankar S: An overview of doxorubicin formulations in cancer therapy. J Cancer Res Ther. 10:853–858. 2014. View Article : Google Scholar : PubMed/NCBI
24	Han YQ, Hong Y, Su XL and Wang JR: Quercetin enhances the anti-leukemic effect of adriamycin. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 22:1555–1560. 2014.(In Chinese). PubMed/NCBI
25	Kong X, Zhang J, Li J, Shao J and Fang L: miR-130a-3p inhibits migration and invasion by regulating RAB5B in human breast cancer stem cell-like cells. Biochem Biophys Res Commun. 501:486–493. 2018. View Article : Google Scholar : PubMed/NCBI
26	Zhang HD, Jiang LH, Sun DW, Li J and Ji ZL: The role of miR-130a in cancer. Breast cancer. 24:521–527. 2017. View Article : Google Scholar : PubMed/NCBI
27	Liu Y, Li Y, Wang R, Qin S, Liu J, Su F, Yang Y, Zhao F, Wang Z and Wu Q: miR-130a-3p regulates cell migration and invasion via inhibition of Smad4 in gemcitabine resistant hepatoma cells. J Exp Clin Cancer Res. 35:192016. View Article : Google Scholar : PubMed/NCBI
28	Zhu X, Zhao H, Lin Z and Zhang G: Functional studies of miR-130a on the inhibitory pathways of apoptosis in patients with chronic myeloid leukemia. Cancer Gene Ther. 22:573–580. 2015. View Article : Google Scholar : PubMed/NCBI
29	Feng C, Ma F, Hu C, Ma JA, Wang J, Zhang Y, Wu F, Hou T, Jiang S, Wang Y and Feng Y: SOX9/miR-130a/CTR1 axis modulates DDP-resistance of cervical cancer cell. Cell Cycle. 17:448–458. 2018. View Article : Google Scholar : PubMed/NCBI
30	Chen T, You Y, Jiang H and Wang ZZ: Epithelial-mesenchymal transition (EMT): A biological process in the development, stem cell differentiation, and tumorigenesis. J Cell Physiol. 232:3261–3272. 2017. View Article : Google Scholar : PubMed/NCBI
31	Lamouille S, Xu J and Derynck R: Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 15:178–196. 2014. View Article : Google Scholar : PubMed/NCBI
32	Dominguez C, David JM and Palena C: Epithelial-mesenchymal transition and inflammation at the site of the primary tumor. Semin Cancer Biol. 47:177–184. 2017. View Article : Google Scholar : PubMed/NCBI
33	Liao TT and Yang MH: Revisiting epithelial-mesenchymal transition in cancer metastasis: The connection between epithelial plasticity and stemness. Mol Oncol. 11:792–804. 2017. View Article : Google Scholar : PubMed/NCBI
34	Lee HH, Jung J, Moon A, Kang H and Cho H: Antitumor and anti-invasive effect of apigenin on human breast carcinoma through suppression of IL-6 expression. Int J Mol Sci. 20:31432019. View Article : Google Scholar
35	Serrano-Gomez SJ, Maziveyi M and Alahari SK: Regulation of epithelial-mesenchymal transition through epigenetic and post-translational modifications. Mol Cancer. 15:182016. View Article : Google Scholar : PubMed/NCBI